GSA Capital Partners’s Novavax NVAX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.34M | Buy |
+165,179
| New | +$1.5M | 0.08% | 339 |
|
|
2025
Q3 | – | Sell |
-113,849
| Closed | -$717K | – | 1955 |
|
|
2025
Q2 | $717K | Buy |
+113,849
| New | +$754K | 0.05% | 676 |
|
|
2024
Q3 | – | Sell |
-20,046
| Closed | -$254K | – | 1891 |
|
|
2024
Q2 | $254K | Buy |
+20,046
| New | +$202K | 0.02% | 1356 |
|
|
2023
Q4 | – | Sell |
-12,024
| Closed | -$87K | – | 1786 |
|
|
2023
Q3 | $87K | Buy |
+12,024
| New | +$96.1K | 0.01% | 1395 |
|
|
2023
Q2 | – | Sell |
-11,561
| Closed | -$80K | – | 1814 |
|
|
2023
Q1 | $80K | Sell |
11,561
-12,758
| -52% | -$117K | 0.01% | 1380 |
|
|
2022
Q4 | $250K | Buy |
24,319
+852
| +4% | +$15K | 0.03% | 1051 |
|
|
2022
Q3 | $427K | Buy |
+23,467
| New | +$1.02M | 0.06% | 694 |
|
|
2022
Q2 | – | Sell |
-5,404
| Closed | -$398K | – | 1681 |
|
|
2022
Q1 | $398K | Buy |
5,404
+3,180
| +143% | +$284K | 0.05% | 707 |
|
|
2021
Q4 | $318K | Buy |
+2,224
| New | +$382K | 0.04% | 888 |
|
|
2019
Q3 | – | Sell |
-33,552
| Closed | -$197K | – | 1612 |
|
|
2019
Q2 | $197K | Buy |
+33,552
| New | +$264K | 0.02% | 1242 |
|
|
2019
Q1 | – | Sell |
-5,386
| Closed | -$198K | – | 1613 |
|
|
2018
Q4 | $198K | Sell |
5,386
-26,784
| -83% | -$1.04M | 0.02% | 1112 |
|
|
2018
Q3 | $1.21M | Sell |
32,170
-9,455
| -23% | -$266K | 0.07% | 550 |
|
|
2018
Q2 | $1.12M | Buy |
41,625
+35,600
| +591% | +$1.2M | 0.06% | 688 |
|
|
2018
Q1 | $253K | Sell |
6,025
-54,733
| -90% | -$2.2M | 0.01% | 1379 |
|
|
2017
Q4 | $1.51M | Buy |
60,758
+4,640
| +8% | +$113K | 0.09% | 353 |
|
|
2017
Q3 | $1.28M | Sell |
56,118
-28,390
| -34% | -$636K | 0.09% | 359 |
|
|
2017
Q2 | $1.94M | Buy |
84,508
+23,568
| +39% | +$462K | 0.13% | 168 |
|
|
2017
Q1 | $1.56M | Buy |
+60,940
| New | +$1.68M | 0.08% | 384 |
|
|
2016
Q2 | – | Sell |
-1,683
| Closed | -$174K | – | 1854 |
|
|
2016
Q1 | $174K | Sell |
1,683
-496
| -23% | -$53.2K | 0.01% | 1516 |
|
|
2015
Q4 | $366K | Sell |
2,179
-17,094
| -89% | -$2.63M | 0.02% | 1351 |
|
|
2015
Q3 | $2.73M | Buy |
19,273
+11,916
| +162% | +$2.67M | 0.13% | 149 |
|
|
2015
Q2 | $1.64M | Sell |
7,357
-1,467
| -17% | -$258K | 0.06% | 521 |
|
|
2015
Q1 | $1.46M | Buy |
+8,824
| New | +$1.43M | 0.06% | 571 |
|
|
2014
Q4 | – | Sell |
-1,792
| Closed | -$149K | – | 1840 |
|
|
2014
Q3 | $149K | Buy |
1,792
+1,177
| +191% | +$106K | 0.01% | 1580 |
|
|
2014
Q2 | $57K | Sell |
615
-1,781
| -74% | -$157K | ﹤0.01% | 1748 |
|
|
2014
Q1 | $217K | Buy |
+2,396
| New | +$268K | 0.02% | 1330 |
|
Other funds holding NVAX
SCM
VPM
VCM
S
GSA Capital Partners's NVAX Position: Q1 2026 in Review
GSA Capital Partners opened a new position in Novavax (NVAX) in Q1 2026: 165,179 shares worth $1.34M. The stake represents 0.08% of the portfolio and ranks #339 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in NVAX as recently as Q2 2025.
GSA Capital Partners first reported a position in NVAX in Q1 2014 and has held it in 26 quarters since. The position peaked at $2.73M in Q3 2015. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.
- GSA Capital Partners held 165,179 shares of Novavax worth $1.34M as of Q1 2026.
- Novavax was a new GSA Capital Partners position in Q1 2026.
- Novavax made up 0.08% of GSA Capital Partners's portfolio in Q1 2026, its #339 holding.
- GSA Capital Partners first reported a position in Novavax in Q1 2014 and has held it in 26 quarters since.
- GSA Capital Partners's Novavax position peaked at $2.73M in Q3 2015.
- 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.